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Fig. S1. Positive ion mode ESI MS spectra of angiotensin II adducts with compounds [Ru(Cl-
tpy)(en)Cl]+ (A), [Ru(Cl-tpy)(dach)Cl]+ (B) and [Ru(Cl-tpy)(bipy)Cl]+ (C).  Inset in each spectrum 
shows isotopic distribution of triply charged ruthenated peptide. Additional peaks at m/z 737.3, 
764.3 and 785.2 for compounds en, dach and bipy, respectively, correspond to doubly charged 
ruthenated angiotensin II.
Fig. S2. Negative ion mode ESI MS spectra of angiotensin II adducts with compounds [Ru(Cl-
tpy)(en)Cl]+ (A), [Ru(Cl-tpy)(dach)Cl]+ (B) and [Ru(Cl-tpy)(bipy)Cl]+ (C).  Inset in each spectrum 
shows isotopic distribution of singly charged ruthenated peptide. Two subsequent peaks in each 
spectrum (at m/z 1515.5 and 1563.6 for en compound, 1571.6 and 1617.6 for dach and 1613.5 
and 1659.5 for bipy compound)  represent mono- and di-formic acid adducts. Signal at 1044.5 in 
each spectrum correspond to free angiotensin II.
Fig. S3. Enlarged positive ion mode LE MSE spectra showing [Ru(Cl-tpy)(en)]-bound HSA 
sequences: DAHK (A), SEVAHR (B), SLHTLFGDK (C), HPDYSVVLLLR (D), DVFLGMFLYEYAR (E) and 
HPYFYAPELLFFAK (F). Target sequences are marked with a black asterisk in each spectrum.
Fig. S4. Enlarged positive ion mode LE MSE spectra showing [Ru(Cl-tpy)(dach)]-bound HSA 
sequences: DAHK (A), SEVAHR (B), SLHTLFGDK (C), HPDYSVVLLLR (D), DVFLGMFLYEYAR (E) and 
HPYFYAPELLFFAK (F). Target sequences are marked with a black asterisk in each spectrum.
Fig. S5. Enlarged positive ion mode LE MSE spectra showing [Ru(Cl-tpy)(bipy)]-bound HSA 
sequences: DAHK (A), SEVAHR (B), SLHTLFGDK (C) and DVFLGMFLYEYAR (D). Target sequences 
are marked with a black asterisk in each spectrum. 
Fig. S6. PLGS generated HE MSE spectrum of 338HPDYSVVLLLR348 HSA sequence adduct with 
compound [Ru(Cl-tpy)(en)Cl]+. The identified precursor is triply positively charged ion with a mass 
of 1732 Da. The identified mass corresponds to the peptide adduct with compound [Ru(Cl-
tpy)(en)Cl]+, after Cl ligand hydrolysis.
Table S1. PLGS software identified HE MSE peptide fragment ions.  marks neutral loss (H2O, NH3).
Peptide sequence Number 
of ions
Fragment ion identity
5SEVAHR10 12 b2, b3, b3, b4, b4, b5,y2, y3, y4, y5, y5, y6
65SLHTLFGDK73 9 y2, y2, y3, y3, y4, y5, y6, y7, y7 
146HPYFYAPELLFFAK159 10 b10, y2, y3, y4, y6, y7, y8, y12, y13, y14
324DVFLGMFLYEYAR336 7 b1, b11, y8, y9, y10, y11, y12
338HPDYSVVLLLR348 13 b2, b5, y2, y3, y4, y5, y6, y7, y8, y8, y9, y10, y11
Fig. S7. Enlarged negative ion mode LE MSE spectra showing [Ru(Cl-tpy)(en)]-bound HSA 
sequences: DAHK (A), SEVAHR (B), SLHTLFGDK (C), HPDYSVVLLLR (D), DVFLGMFLYEYAR (E) and 
HPYFYAPELLFFAK (F). Target sequences are marked with a black asterisk in each spectrum.
Fig. S8. Enlarged negative ion mode LE MSE spectra showing [Ru(Cl-tpy)(dach)]-bound HSA 
sequences: DAHK (A), SEVAHR (B), SLHTLFGDK (C), HPDYSVVLLLR (D), DVFLGMFLYEYAR (E) and 
HPYFYAPELLFFAK (F). Target sequences are marked with a black asterisk in each spectrum.
Fig. S9. Enlarged negative ion mode LE MSE spectra showing [Ru(Cl-tpy)(dach)]-bound HSA 
sequences: DAHK (A), SEVAHR (B), SLHTLFGDK (C) and DVFLGMFLYEYAR (D). Target sequences 
are marked with a black asterisk in each spectrum. 
Fig. S10. HSA structure with major drug binding sites (A) and spatial localisation of MS-identified 
sequences for the binding of compounds [Ru(Cl-tpy)(en)Cl]+, [Ru(Cl-tpy)(dach)Cl]+ and [Ru(Cl-
tpy)(bipy)Cl]+.
Fig. S11. HSA binding sites for chloro, hydroxo and aqua forms of compounds [Ru(Cl-tpy)(en)Cl]+, 
[Ru(Cl-tpy)(dach)Cl]+ and [Ru(Cl-tpy)(bipy)Cl]+. Chloro forms are shown green, hydroxo red and 
aqua forms are shown blue. Target MS-identified HSA sequences are highlighted black.
Table S3. Binding energies of chloro, hydroxo and aqua forms of compounds [Ru(Cl-tpy)(en)Cl]+, 
[Ru(Cl-tpy)(dach)Cl]+ and [Ru(Cl-tpy)(bipy)Cl]+, for each HSA binding site. Binding energies of 
chloro complexes that correspond to MS-identified sequences are highlighted green, while 
hydroxo complexes are marked red. The remaining binding energy values that most probably 
correspond to non-covalent interactions are black.
Binding energy (kcal/mol)Ru(II)
compound
Binding 
site No -Cl -OH -H2O
1
[RuL(4’-Cl-tpy)(en)]
1
2
3
4
5
6
7
-8,12 
-7,27
-7,22
-7,09
-6,99
-6,83 
-6,74  
-7,80
-6,32
-5,84
-5,77
-5,42
-5,34
-5,22
-7,90
-7,83
-7,40
-
-
-
-
2
[RuL(4’-Cl-tpy)(dach)]
1
2
3
4
5
6
7
8
9
-9,14
-8,67
-8,53
-8,53
-8,38
-8,37
-7,46
-7,18
-
-8,56
-7,75
-7,08
-6,93
-6,82
-6,77
-6,55
-6,48
-6,47
-3,02
-2,95
-2,73
-2,66
-
-
-
-
-
3
[RuL(4’-Cl-tpy)(bipy)]
1
2
-7,97
-6,98 
-6,33
-5,84
-1,78
-1,44
